MARKET

CLRB

CLRB

Cellectar
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.383
-0.077
-5.28%
Opening 15:43 05/06 EDT
OPEN
1.450
PREV CLOSE
1.460
HIGH
1.470
LOW
1.360
VOLUME
439.60K
TURNOVER
--
52 WEEK HIGH
2.980
52 WEEK LOW
1.010
MARKET CAP
72.92M
P/E (TTM)
-1.4499
1D
5D
1M
3M
1Y
5Y
8-K: Cellectar Biosciences, Inc.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________ FORM 8-K ___________________ CURRENT REPORT (EDGAR Online via...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 2d ago
Cellectar gets notification of formal grant from Australian and Mexican patent authorities
Cellectar Biosciences (CLRB) announces that it has received notification of formal grant of the patent titled, "Phospholipid-Ether Analogs as Cancer-Targeting Drug Vehicles" by the Eurasian, Australian and Mexican patent authorities.The patent
Seekingalpha · 04/27 12:48
Cellectar Strengthens Global IP Position with Phospholipid Drug Conjugate Composition of Matter Patent in Eurasia, Australia, and Mexico
New patent covers phospholipid-ether analogs combined with various small molecule chemotherapeutics and methods of use for PDCs™ FLORHAM PARK, N.J., April 27, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopha...
GlobeNewswire · 04/27 12:39
Von Hippel-Lindau Market is Expected to Witness Rapid Growth by 2030 | Astellas US Holding, Inc., Advantagene, Inc, Burzynski Research Institute, Inc., Cellectar Biosciences, Inc., Direct Therapeutics, Inc. and Others
Apr 15, 2021 (MARKITWIRED via COMTEX) -- Von Hippel-Lindau is an autosomal disease can cause malignant tumor due to the mutation in the Von Hippel-Lindau...
Markitwired · 04/15 12:44
Neuroblastoma Drugs Market Size, Share, Trends & Growth, 2028
Mar 31, 2021 (AmericaNewsHour) -- Research Nester published a report titled "Neuroblastoma drugs market– Global Demand Analysis and Opportunity Outlook...
AmericaNewsHour · 03/31 13:20
Global Von Hippel-Lindau Treatment Market 2020 Size, Market Share, Key Players, Segmentation Development and Forecast by 2025
Mar 29, 2021 (CDN Newswire via Comtex) -- Global Von Hippel-Lindau Treatment Market Growth (Status and Outlook) 2020-2025 is a resource, which provides...
CDN Newswire · 03/29 19:19
Are Insiders Buying Cellectar Biosciences, Inc. (NASDAQ:CLRB) Stock?
It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be...
Simply Wall St. · 03/28 09:29
Cellectar Biosciences Inc. (NASDAQ: CLRB) Featured in Virtual Coverage of the 33rd Annual ROTH Conference
Mar 16, 2021 (Investor Brand Network via COMTEX) -- Cellectar Biosciences Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company, is focused on...
Investor Brand Network · 03/16 19:22
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CLRB. Analyze the recent business situations of Cellectar through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CLRB stock price target is 5.98 with a high estimate of 10.00 and a low estimate of 3.000.
EPS
Institutional Holdings
Institutions: 53
Institutional Holdings: 18.48M
% Owned: 35.05%
Shares Outstanding: 52.73M
TypeInstitutionsShares
Increased
6
3.16M
New
25
11.56M
Decreased
2
173.64K
Sold Out
6
302.39K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.18%
Pharmaceuticals & Medical Research
-0.60%
Key Executives
Chairman/Independent Director
Douglas Swirsky
President/Chief Executive Officer/Director
James Caruso
Chief Financial Officer/Vice President
Dov Elefant
Vice President
John Friend
Other
Jarrod Longcor
Independent Director
Frederick Driscoll
Independent Director
Stefan Loren
Independent Director
John Neis
No Data
  • All
  • Financials
  • Insiders
More
About CLRB
Cellectar Biosciences, Inc. is a clinical-stage biopharmaceutical company, which is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The Company is engaged in developing phospholipid ether-drug conjugates (PDCs) for the treatment and diagnostic imaging of cancer. The Company’s research and development program is based on its PDC cancer-targeting delivery platform. Its pipeline consists of pre-clinical and clinical product candidates, including radiotherapeutic and chemotherapeutic PDC's. Its PDC therapeutic, CLR 131 is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells. The Company’s product pipeline also includes one preclinical PDC chemotherapeutic program (CLR 1900). The CLR 1900 Series is targeted for solid tumors with a payload that inhibits mitosis a validated pathway for treating cancers.

Webull offers kinds of Cellectar Biosciences Inc stock information, including NASDAQ:CLRB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLRB stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CLRB stock methods without spending real money on the virtual paper trading platform.